Verseau Therapeutics

About:

Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.

Website: https://www.verseautx.com/

Twitter/X: verseautx

Top Investors: Alexandria Venture Investments, Highlight Capital, Yonghua Capital, 20/20 HealthCare Partners, The Mark Foundation for Cancer Research

Description:

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients from immunotherapy.